ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02281084
Recruitment Status : Recruiting
First Posted : November 3, 2014
Last Update Posted : April 12, 2018
Sponsor:
Information provided by (Responsible Party):
Celgene

Brief Summary:

Evaluate the safety and efficacy of CC-486 in Subjects with Myelodysplastic Syndromes who failed to achieve an objective response post iHMA treatment

Reason for removing the Combo arm: Due to difficulties with dose-finding, the durvalumab plus CC-486 combination arm is closed to enrollment


Condition or disease Intervention/treatment Phase
Myelodysplastic Syndromes Drug: CC-486 (ORAL AZACITIDINE) Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group to Evaluate the Efficacy and Safety of Cc-486 (Oral Azacitidine) Alone in Combination With Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve an Objective Response to Treatment With Azacitidine for Injection or Decitabine
Actual Study Start Date : July 6, 2015
Estimated Primary Completion Date : January 3, 2022
Estimated Study Completion Date : June 30, 2022


Arm Intervention/treatment
Experimental: Monotherapy
Dispense CC-486 (Oral azacitidine) alone to subjects divided in 2 Cohorts of Stable versus Progressive disease
Drug: CC-486 (ORAL AZACITIDINE)
200 mg CC-486 (Oral Azacitidine) will be given for the first 21 days of each 28-day treatment cycle
Other Name: CC-486



Primary Outcome Measures :
  1. Overall Response Rate [ Time Frame: Up to 3 years ]
    Subjects achieving an objective response according to the modified IWG -international working group- 2006 criteria


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: Up to 3 years ]
    Subjects surviving until the end of follow-up period

  2. Time to onset of responses [ Time Frame: Up to 3 years ]
    Number of days from starting treatment to the occurrence of response by the end of follow-up as per modified IWG -international working group- 2006 criteria

  3. Duration of responses [ Time Frame: Up to 3 years ]
    Number of days from beginning of response (modified IWG -international working group- criteria) to relapse during the treatment and follow-up period

  4. Progression free survival [ Time Frame: Up to 3 years ]
    Number of days from starting treatment to disease progression or death from any cause

  5. Stabilization of progression disease [ Time Frame: Up to 3 years ]
    Subjects with progressive disease at baseline achieving stable disease status

  6. Time to achieving stable disease [ Time Frame: Approximately 6 months ]
    Number of days from starting treatment to first documented Stable Disease

  7. Duration of stable disease [ Time Frame: Up to 3 years ]
    Time from first documented Stable Disease to Disease Progression

  8. Progression to AML [ Time Frame: Up to 3 years ]
    subjects with disease progression to FAB-defined (French American British) AML (Acute Myeloid Leukemia)

  9. Time to AML progression [ Time Frame: Up to 3 years ]
    Time from starting treatment to onset of AML (Acute Myeloid Leukemia)

  10. Adverse Events [ Time Frame: Up to 3 years ]
    Type, frequency, severity of AEs (adverse events) and relationship of AEs (adverse events) to CC-486

  11. Pharmacokinetic - Cmax [ Time Frame: Up to 2 years ]
    Maximum observed plasma concentration

  12. Pharmacokinetic - AUCt [ Time Frame: Up to 2 years ]
    Area under the plasma concentration-time

  13. Pharmacokinetic - AUCinf [ Time Frame: Up to 2 years ]
    Area under the plasma concentration-time curve from Time 0 extrapolated to infinity

  14. Pharmacokinetic - Tmax [ Time Frame: Up to 2 years ]
    Time to Cmax, obtained directly from the observed concentration versus time data.

  15. Pharmacokinetic - t1/2 [ Time Frame: Up to 2 years ]
    Terminal phase half-life in plasma

  16. Pharmacokinetic - CL/F [ Time Frame: Up to 2 years ]
    Apparent total clearance

  17. Pharmacokinetic - Vz/F [ Time Frame: Up to 2 years ]
    volume of distribution (Vz/F)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, ≥ 18 years of age at the time of signing the informed consent document
  2. Documented diagnosis of MDS (MYELODYSPLASTIC SYNDROMES), classified according to FAB (FRENCH-AMERICAN BRITISH) classification criteria
  3. Adequate course of treatment with an injectable hypomethylating agent (azacitidine for injection or decitabine) as the last therapeutic intervention for MDS (MYELODYSPLASTIC SYNDROMES) prior to beginning screening for this study. Adequate is defined as:

    - having received at least 6 consecutive 4-week treatment cycles with azacitidine for injection, or

    - having received at least 4 consecutive 6-week treatment cycles with decitabine (3-day regimen) or at least 6 consecutive 4-week treatment cycles with decitabine (5-day regimen), or

    - having demonstrated inability to tolerate treatment with an injectable hypomethylating agent because of unacceptable drug-related toxicity after at least 3 months of attempted treatment: Three 28-day cycles of azacitidine for injection or decitabine 5-day regimen; two 42-day cycles of decitabine 3-day regimen.

  4. Documented disease progression or stable disease as best response to treatment (or attempted treatment) with azacitidine for injection or decitabine. Those achieving an objective response to treatment regimen with an injectable Hypomethylating agent (HMA) are excluded from participation in this study.

    Definitions of disease progression are modified from IWG (INTERNATIONAL WORKING GROUP) 2006 criteria and include:

    - Pre-injectable HMA (HYPOMETHYLATING AGENT) baseline bone marrow myeloblasts:

    a. Less than 5%: ≥ 100% increase to ≥ 8% blasts b. ≥ 5%: ≥ 50% increase to ≥ 10% blasts Note: ≥ 30% blasts is considered AML (ACUTE MYELOID LEUKEMIAT) per FAB (FRENCH-AMERICAN BRITISH)classification. Subjects known to have ≥ 30% blasts are not eligible for inclusion in this study. RECOG (Eastern Cooperative Oncology Group) nizing limitations of blast cell quantification, this protocol will allow subjects with pre-enrollment bone marrow blast counts up to 33% on the screening bone marrow examination to be considered for inclusion. Assessment may be made according to local bone marrow examination to facilitate enrollment of eligible subjects into the treatment phase of the study.

    - Any clinical worsening from pre-injectable HMA (HYPOMETHYLATING AGENT) baseline condition, including:

    1. sustained clinically-significant worsening (investigator's assessment) from baseline granulocyte, platelet, or hemoglobin values (≥ 2 values, separated by ≥ 2 weeks)

      - worsening granulocytes should be ≥ 50% decrease from pre-injectable HMA (HYPOMETHYLATING AGENT) baseline value

      • worsening platelets should be ≥ 50% decrease from pre-injectable HMA (HYPOMETHYLATING AGENT) baseline value (untransfused)
      • worsening hemoglobin should be ≥ 1.5 g/dL decrease from preinjectable HMA (HYPOMETHYLATING AGENT) baseline value in subjects not receiving RBC (RED BLOOD CELL) transfusions
    2. meaningful worsening in RBC (RED BLOOD CELL) or platelet transfusion requirement

    Definition of stable disease is based on modified IWG (INTERNATIONAL WORKING GROUP) 2006 criteria:

    - Failure to achieve any objective response (CR - complete remission, PR - partial remissino, mCR - marrow complete remission, or HI - hematologic improvement), but no evidence of disease progression within the 8 weeks leading to the subject's first dose of IP (INVESTIGATIONAL PRODUCT) in this study (Cycle 1, Day 1)

  5. Have the last dose of the prior treatment regimen (injectable HMA (HYPOMETHYLATING AGENT) - azacitidine for injection or decitabine) not more than 16 weeks prior to screening for this study (date of informed consent signature).
  6. No less than 3 weeks between the last dose of the prior treatment regimen (injectable HMA (HYPOMETHYLATING AGENT) - azacitidine for injection or decitabine) and the planned date of first dose of IP (IINVESTIGATIONAL PRODUCT).
  7. Have an ECOG (EASTERN COOPERATIVE ONCOLOGY GROUP) performance status of 0, 1, or 2
  8. Females subjects of childbearing potential (FCBP)1 may participate, providing they meet the following conditions:

    1. Have two negative pregnancy tests as verified by the investigator prior to starting any IP therapy: serum pregnancy test at screening and negative serum or urine pregnancy test (investigator's discretion) within 72 hours prior to starting treatment with IP (Cycle 1, Day 1). They must agree to ongoing pregnancy testing during the course of the study (before beginning each subsequent cycle of treatment), and after the last dose of any IP. This applies even if the subject practices complete abstinence2 from heterosexual contact.
    2. Agree to practice true abstinence2 (which must be reviewed on a monthly basis and source documented) or agree to the use of highly effective methods of contraception from 28 days prior to starting azacitidine, and must agree to continue using such precautions while taking azacitidine (including dose interruptions) and for up to 90 days after the last dose of azacitidine. Cessation of contraception after this point should be discussed with a responsible physician
    3. Agree to abstain from breastfeeding during study participation and for at least 90 days after the last dose of IP.

Note that the screening serum pregnancy test can also be used as the test prior to starting IP (Investigational Product) if it is performed within the 72-hour timeframe.

9. Male subjects must:

  1. Male subjects must:

    1. Either practice true abstinence2 from heterosexual contact (which must be reviewed on a monthly basis) or agree to avoid fathering a child, to use highly effective methods of contraception, male condom plus spermicide during sexual contact with a pregnant female or a female of child bearing potential (even if he has undergone a successful vasectomy) from starting dose of IP (Cycle 1 Day 1), including dose interruptions through 90 days after receipt of the last dose of azacitidine.
  2. Refrain from semen or sperm donation while taking IP and for at least 90 days after the last dose of IP.

    10. Understand and voluntarily sign an informed consent document prior to any study-related assessments or procedures conducted.

    11. Be able to adhere to the study visit schedule and other protocol requirements.

    12. Understand and voluntarily sign a biomarker-specific component of the informed consent document prior to any study-related procedures conducted.

Exclusion Criteria:

  1. Rapidly-progressing MDS (MYELODYSPLASTIC SYNDROMES), defined as:

    1. Known clinically-significant doubling in marrow or perIP (INVESTIGATIONAL PRODUCT) heral blood blast percentage (to ≥ 20%) in the 8-week period leading to the first dose of IP (INVESTIGATIONAL PRODUCT) (Cycle 1, Day 1)
    2. ≥100% increase in WBC count (myeloid cell line and monocyte series) within the 8-week period leading to Cycle 1, Day 1
  2. Acute myelogenous leukemia (AML (ACUTE MYELOID LEUKEMIA) - FAB (FRENCH-AMERICAN-BRITISH) classification: ≥ 30% blasts in bone marrow). Subjects known to have ≥ 30% blasts are not eligible for inclusion in this study. Recognizing limitations of blast cell quantification, this protocol will allow subjects with pre-enrollment (screening/baseline) bone marrow blast counts up to 33% to be considered for inclusion.
  3. Prior allogeneic stem cell transplant
  4. Prior exposure to the investigational oral formulation of decitabine, or other oral azacitidine derivative at any time in the subject's prior history
  5. Prior or ongoing response (IWG 2006: HI, PR, CR, or marrow CR) to treatment with azacitidine for injection or decitabine, at any time in the subject's prior history, which includes relapsed disease
  6. Ongoing medically significant adverse events from previous treatment, regardless of the time period
  7. Use of any of the following within 28 days prior to the first dose of IP (INVESTIGATIONAL PRODUCT):

    1. thrombopoiesis-stimulating agents ([TSAs]; eg, Romiplostim, Eltrombopag, Interleukin-11)
    2. ESAs (Erythropoiesis stimulating agent) and other RBC (Red blood cell) hematopoietic growth factors (eg, interleukin-3)
    3. hydroxyurea
  8. Concurrent use of corticosteroids unless the subject is on a stable or decreasing dose for ≥ 1 week prior to enrollment for medical conditions other than MDS (MYELODYSPLASTIC SYNDROMES)
  9. History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism or excretion of the IP (INVESTIGATIONAL PRODUCT) and/or predispose the subject to an increased risk of gastrointestinal toxicity
  10. Prior history of malignancies, other than MDS (MYELODYSPLASTIC SYNDROMES), unless the subject has been free of the disease for ≥ 3 years. However, subjects with the following history/concurrent conditions are allowed:

    1. Basal or squamous cell carcinoma of the skin
    2. Carcinoma in situ of the cervix
    3. Carcinoma in situ of the breast
    4. Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system)
  11. Significant active cardiac disease within the previous 6 months, including:

    1. New York Heart Association (NYHA) class IV congestive heart failure;
    2. Unstable angina or angina requiring surgical or medical intervention; and/or
    3. Myocardial infarction
  12. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)
  13. Known Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV) infection, or evidence of active Hepatitis B Virus (HBV) infection
  14. Any of the following laboratory abnormalities:

    1. Serum AST/SGOT (Aspartate transaminase / Serum glutamic oxaloacetic transaminase) or ALT/SGPT (Alanine aminotransaminase / Serum glutamic pyruvate transaminase) > 2.5 x ULN (upper limit of normal)
    2. Serum total bilirubin > 1.5 x ULN (upper limit of normal). Higher levels are acceptable if these can be attributed to active red blood cell precursor destruction within the bone marrow (ie, ineffective erythropoiesis). Subjects are excluded if there is evidence of autoimmune hemolytic anemia manifested as a corrected reticulocyte count of > 2% with either a positive Coombs' test or over 50% of indirect bilirubin
    3. Serum creatinine > 2.5 x ULN (upper limit of normal)
    4. Absolute WBC (white blood cell) count ≥ 20 x 109/L
  15. Known or suspected hypersensitivity to azacitidine, mannitol, its constituents, or to any other humanized monoclonal antibody
  16. Pregnant, planning to become pregnant starting from 28 days prior to receiving CC-486 throughout your participation in the study, and for at least 90 days following your last dose of study treatment, or breast-feeding females
  17. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
  18. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
  19. Any condition that confounds the ability to interpret data from the study, including known or suspected conditions other than MDS (MYELODYSPLASTIC SYNDROMES), associated with anemia
  20. Having received any prior MAb (monoclonal antibodies) against CTLA-4 (cytotoxic T lymphocyte-associated antigen), PD-1, or PD-L1 or having received other investigational MAbs (monoclonalantibodies) within 6 months
  21. Clinical evidence of central nervous system (CNS) or pulmonary leukostasis, or CNS leukemia
  22. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis, Crohn's disease], diverticulitis with the exception of a prior episode that has resolved or diverticulosis, celiac disease, irritable bowel disease, or other serious gastrointestinal chronic conditions associated with diarrhea; systemic lupus erythematosus; Wegener's syndrome [granulomatosis with polyangiitis]; myasthenia gravis; Graves' disease; rheumatoid arthritis; hypophysitis, uveitis; etc) within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:

    1. Subjects with vitiligo or alopecia;
    2. Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement for ≥ 3 months; or
    3. Subjects with psoriasis not requiring systemic treatment
  23. History of primary immunodeficiency
  24. Active myeloproliferative neoplasms (MPN) and chronic myelomonocytic leukemia (CMML)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02281084


Contacts
Contact: Associate Director, Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@celgene.com

  Show 67 Study Locations
Sponsors and Collaborators
Celgene
Investigators
Study Director: DU Lam, MD Celgene

Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT02281084     History of Changes
Other Study ID Numbers: CC-486-MDS-006
First Posted: November 3, 2014    Key Record Dates
Last Update Posted: April 12, 2018
Last Verified: April 2018

Keywords provided by Celgene:
Keywords provided by Celgene:
myelodysplastic syndromes
MDS
azacitidine
oral azacitidine (CC-486)
decitabine
intermediate-1
intermediate-2 and high risk myelodysplastic syndromes (MDS)
proliferative chronic myelomonocytic leukemia (CMML)
Chronic
iHMA (injectable hypomethylating agents)
PD-L1

Additional relevant MeSH terms:
Syndrome
Myelodysplastic Syndromes
Preleukemia
Disease
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms
Azacitidine
Decitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors